Fri.Mar 08, 2019

Venture investors and startup execs say they don’t need Elizabeth Warren to defend them from big tech

TechCrunch LA

Responding to Elizabeth Warren’s call to regulate and break up some of the nation’s largest technology companies, the venture capitalists that invest in technology companies are advising the presidential hopeful to move slowly and not break anything.

SpaceX Crew Dragon Set For Splashdown Early Friday Morning


With the first launch of an astronaut-capable spacecraft by Los Angeles-based SpaceX , last weekend, was a success, SpaceX is now attempting to return its Crew Dragon spacecraft to earth this morning. According to NASA and SpaceX, at 2:32 a.m. EST, the Crew Dragon undocked from the International Space Station, and was set to splash down in the Atlantic Ocean around 8:45 a.m.

SpaceX 109

Startup Boost Applications Deadline

SoCal Tech Calendar

Thursday, March 14, 2019 -- Startup Boost Applications Deadline. We are a no fee / no equity 6 week mentorship program. See [link] (more

Equity 100

ResMed Buys Korea's HB Healthcare


Carlsbad-based ResMed , which develops patient monitoring and healthcare software for the sleep and respiratory care market, said late Thursday that it has acquired South Korean company HB Healthcare (HBH). According to ResMed, the deal will help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. Financial details of the acquisition were not announced.

Custom 109

San Diego Life Sciences Roundup: ResMed, Alexandria GradLabs & More


Spring has sprung, and it’s shaping up to be another busy season for San Diego’s life sciences community. As we head into the weekend, crossing our fingers that the seemingly endless rain showers will be replaced by our usual sunshine, here’s a quick rundown of some recent news developments. —ResMed (NYSE: RMD ) acquired a South Korea-based medical equipment provider, the company said Friday. Financial terms of the deal weren’t disclosed.

Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More


In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration, which is the most powerful regulator of medical products in the world. It wasn’t a high bar to clear. Libertarians who had questioned some of the basic premises of the FDA were in the mix, and even their laissez-faire attitudes had some advocates of a speedier agency worried, as Xconomy reported in early 2017. Still, Gottlieb had spent time in the George W.